博雅生物(300294.SZ):擬轉讓所持有的羅益生物11.68%的股權
格隆匯7月8日丨博雅生物(300294.SZ)公佈,公司於2021年7月7日召開第七屆董事會第三次會議,審議通過了《關於轉讓羅益(無錫)生物製藥有限公司股權的議案》,公司擬以19272萬元的價格轉讓持有的羅益(無錫)生物製藥有限公司(“羅益生物”)合計11.68%的股權,其中,成都普瑞邦企業管理諮詢有限公司擬以16500萬元的價格受讓羅益生物10%的股權,湖州泉水叮咚企業管理合夥企業(有限合夥)擬以2772萬元的價格受讓羅益生物1.68%的股權。
截至目前,公司僅持有羅益生物11.68%的少數股權,與羅益生物的業務協同相對有限,且公司未來戰略發展的重心將逐步聚焦於血液製品業務。為此公司擬出售所持有的羅益生物股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.